Arcturus Therapeutics Holdings Inc. cash flow statement
In fiscal 2025, Arcturus Therapeutics Holdings Inc.'s operations generated −$74.3m of cash; it spent $230,000 on capital projects, leaving free cash flow of −$74.5m.
Cash flow statement
| Fiscal year | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −21 | −6 | −43 | −135 | 32 | −18 | −60 | −74 | −73 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 2 | 3 | 4 | 3 | 3 |
| Stock-based pay | 1 | 2 | 7 | 29 | 31 | 35 | 38 | 25 | 21 |
| Capital spending | 1 | 1 | 2 | 3 | 8 | 3 | 1 | 0 | 0 |
| Free cash flow | −22 | −7 | −45 | −138 | 24 | −21 | −60 | −75 | −73 |
| Free cash flow after stock pay | −23 | −9 | −51 | −167 | −6 | −56 | −98 | −100 | −94 |
| Shares issued | — | 21 | 424 | — | — | — | — | 12 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −24 | −0 | −35 | −6 | −17 | −16 | −19 | −20 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 9 | 9 | 7 | 6 | 6 | 7 | 4 | 4 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 |
| Free cash flow | −24 | −0 | −35 | −6 | −17 | −16 | −19 | −20 |
| Free cash flow after stock pay | −33 | −9 | −42 | −12 | −23 | −23 | −24 | −24 |
Compare with peers
- Tonix Pharmaceuticals Holding Corp. cash flow
- Monte Rosa Therapeutics, Inc. cash flow
- Stoke Therapeutics, Inc. cash flow
- Abeona Therapeutics Inc. cash flow
- Crispr Therapeutics AG cash flow
Head to head: ARCT vs TNXPARCT vs GLUEARCT vs STOK
More: Biotechnology stocks compared, Health Care sector, rankings of US companies